# ACIU catalysts: AC Immune SA PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aciu/catalysts

> AC Immune SA (ACIU) has 2 upcoming catalysts. The next is the aci-7104.056 at dose a primary completion, June 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, quarter only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AC Immune SA |
| Ticker | ACIU (Nasdaq) |
| SEC CIK | 1651625 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aciu |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [ACI-7104 trial start](https://sec-api.dev/pdufa/aci-7104) | ACIU |  | completed | "The VacSYn trial commenced in July 2023 with the dosing of the first patient and is progressing well with over 30 patients randomized in Part 1 of the study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000110465926090704/aciu-20260630xex99d2.htm)) |
| 2025 | [ACI-15916 trial start](https://sec-api.dev/pdufa/aci-15916) | ACIU |  | scheduled | "ACI-15916, our next-generation a-syn-PET tracer for PD is advancing towards clinical development with initiation of a Phase 1 study expected in 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651625/000155837025002855/aciu-20241231x20f.htm)) |
| Q2 2025 | [ACI-7104 interim data readout](https://sec-api.dev/pdufa/aci-7104) | ACIU |  | scheduled | "Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000155837025005922/aciu-20250430xex99d3.htm)) |
| 2H 2025 | [ACI-15916 topline data readout](https://sec-api.dev/pdufa/aci-15916) | ACIU |  | scheduled | "The readout from this study is expected in H2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000110465925105896/aciu-20251104xex99d2.htm)) |
| 2H 2025 | [ACI-15196 topline data readout](https://sec-api.dev/pdufa/aci-15196) | ACIU |  | scheduled | "The Phase 1 trial in PD will be initiated in Q1 2025, and the readout from this study is expected in H2 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651625/000155837025002855/aciu-20241231x20f.htm)) |
| late 2025 | [ACI-7104 interim data readout](https://sec-api.dev/pdufa/aci-7104) | ACIU |  | scheduled | "o Based on further interim results to be reported later in 2025, including pharmacodynamic and biomarker data, AC Immune may decide to initiate Part 2 of VacSYn, with the aim of establishing early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000155837025005922/aciu-20250430xex99d2.htm)) |
| late 2025 | [ACI-24 interim data readout](https://sec-api.dev/pdufa/aci-24) | ACIU |  | scheduled | "Further interim results from Part 1 of the VacSYn trial of ACI-7104.056 are expected later this year, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment around year end, with interim results thereafter." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d3.htm)) |
| Dec 2025 | [ACI-19626 interim data readout](https://sec-api.dev/pdufa/aci-19626) | ACIU |  | scheduled | "The Phase 1 trial was initiated in January 2025 and the interim readout from this study is expected in Dec 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651625/000155837025002855/aciu-20241231x20f.htm)) |
| Dec 2025 | [ACI-7104 interim data readout](https://sec-api.dev/pdufa/aci-7104) | ACIU |  | completed, positive | "Positive interim results from the Phase 2 VacSYn trial of ACI-7104 in early PD were reported in December 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326008815/dp248283_exh9901.htm)) |
| 1H 2026 | [ACI-15916 topline data readout](https://sec-api.dev/pdufa/aci-15916) | ACIU |  | scheduled | "The readout from this study is expected in H1 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651625/000110465926027342/aciu-20251231x20f.htm)) |
| early 2026 | [ACI-24 interim data readout](https://sec-api.dev/pdufa/aci-24) | ACIU |  | scheduled | "Third Alzheimer's disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d3.htm)) |
| February 24, 2026 | [ACI-19764 trial start](https://sec-api.dev/pdufa/aci-19764) | ACIU |  | completed | "ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that the first participant has been dosed in a Phase 1 clinical trial of ACI-19764, an orally administered small molecule inhibitor of the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326002519/dp241987_ex9901.htm)) |
| April 30, 2026 | [ACI-24 trial start](https://sec-api.dev/pdufa/aci-24) | ACIU | Alzheimer's Disease triggers milestone payment, as | completed | "Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326006499/dp245995_ex9901.htm)) |
| 2H 2026 | [ACI-19764 interim data readout](https://sec-api.dev/pdufa/aci-19764) | ACIU |  | scheduled | "Initial data from the Phase 1 trial are expected in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651625/000095010326002519/dp241987_ex9901.htm)) |
| 2H 2026 | [ACI-19764 trial start](https://sec-api.dev/pdufa/aci-19764) | ACIU |  | scheduled | "Additionally, the Company's program, ACI-19764, an NLRP3 inflammasome inhibitor, is imminently expected to start dosing healthy volunteers in a Phase 1 trial with results anticipated in the second half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1651625/000095010326002195/dp241689_6k.htm)) |
| June 2028 | [Aci-7104.056 at dose a primary completion](https://sec-api.dev/pdufa/aci-7104-056-at) | ACIU | Parkinson Disease; Parkinson Disease 6, Early-Onset | scheduled | "NCT06015841 (A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AC Immune SA." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015841)) |
| Jun to Sep 2028 | [Aci-7104.056 at dose a topline data readout](https://sec-api.dev/pdufa/aci-7104-056-at) | ACIU | Parkinson Disease; Parkinson Disease 6, Early-Onset | scheduled | "NCT06015841 (A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AC Immune SA." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015841)) |

## Drugs

- [ACI-15196](https://sec-api.dev/pdufa/aci-15196): 
- [ACI-15916](https://sec-api.dev/pdufa/aci-15916): 
- [ACI-19626](https://sec-api.dev/pdufa/aci-19626): 
- [ACI-19764](https://sec-api.dev/pdufa/aci-19764): 
- [ACI-24](https://sec-api.dev/pdufa/aci-24): alzheimer's disease triggers milestone payment, as, alzheimer's disease
- [ACI-7104](https://sec-api.dev/pdufa/aci-7104): 
- [Aci-7104.056 at dose a](https://sec-api.dev/pdufa/aci-7104-056-at): Parkinson Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aciu/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACIU catalysts: AC Immune SA PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aciu/catalysts

```bibtex
@misc{secapidev_companies_aciu_catalysts_20261116,
  title        = {ACIU catalysts: AC Immune SA PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aciu/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aciu_catalysts_20261116","title":"ACIU catalysts: AC Immune SA PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aciu/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
